Cervical cancer
Also known as: Cancer of the cervix, Uterine cervical cancer, Cervical carcinoma, Malignant neoplasm of the cervix
Cervical carcinoma involves malignant neoplasms of the uterine cervix, predominantly associated with persistent high-risk human papillomavirus (HPV) infection. Primary management, including diagnostic procedures and clinical staging, is conducted by specialist gynaecological oncology teams via surgical resection, radiotherapy, and systemic pharmacotherapy. Chinese medicine is strictly adjunctive for symptomatic support. A meta-analysis of eight trials (n=627) reported improvements in pain and functional status when acupuncture was integrated with conventional care; however, insufficient detail in available abstracts precludes definitive or generalisable conclusions. Research regarding post-operative urinary retention and immunotherapy side effects currently consists of protocols without published findings. These do not validate benefits for bladder recovery, tumour response, or overall survival. The documented patterns and formulas provide a traditional framework for clinical assessment and do not constitute validated treatments for malignancy.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Adhere to all oncology consultations and maintain prescribed medical and surveillance protocols unless modified by the specialist team.
- •Maintain a concise clinical log of pain, sleep, appetite, bowel symptoms, and urinary function to facilitate clinical review.
- •Consume manageable nutritional portions and maintain hydration levels according to oncology or dietician recommendations.
- •Balance periods of rest with clinician-approved physical activity and engage with appropriate emotional or practical support services as required.
Cautions & Contraindications
- •Do not use acupuncture to postpone catheter management, a supervised voiding trial or investigation of postoperative urinary retention. EA and TEAS findings in the supplied records are protocols only, not demonstrated alternatives to standard care.[,]
- •Defer needling pending oncology clearance in clinically significant thrombocytopenia, neutropenia, active bleeding or infection. Avoid tumour sites, wounds, inflamed irradiated skin and areas with compromised lymphatic drainage. These are clinical precautions; the supplied pain abstract does not establish safe blood-count thresholds or site-specific safety.[]
- •Do not claim acupuncture enhances immunotherapy response or survival, or start herbs during immunotherapy without oncology-pharmacist review. The supplied combination study is a protocol and provides no completed efficacy or interaction data.[]
When to reassess or seek care again
Record baseline pain on a 0–10 scale, breakthrough analgesic use, sleep disruption and a patient-selected functional goal. Review tolerability each visit and overall benefit after 2 weeks or 4 sessions. Continue only with meaningful patient-reported benefit, such as a 2-point pain reduction or improved function without increased adverse effects. Reassess or discontinue ineffective adjunctive treatment. Escalate immediately for red flags and refer promptly for worsening pain, weight loss or function. For postoperative urinary retention, use the surgical team's catheter and post-void residual review schedule; never remove a catheter based on subjective improvement alone.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Journal of pain research · 2026
- Journal of pain and symptom management · 2026
- International journal of women's health · 2026
- Frontiers in oncology · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
